Tag Archives: Daniel Perlman

The impact of depression treatment persistence on total healthcare costs

Depression is a prevalent and costly disorder. Existing research has shown that many patients suffering from behavioral health conditions, including depression, receive inadequate or no treatment for these disorders. Inadequate treatment often occurs when patients discontinue their prescribed courses of treatment.

The purpose of this research report is to attempt to quantify the impact of depression treatment persistence on post-treatment healthcare costs. Is persistent treatment associated with future healthcare cost savings? Do patients who receive more depression treatment or continue treatment have lower total healthcare cost growth post-treatment than those who received less treatment or discontinued treatment? We conducted a study from a large national medical claims database and compared the relative change in total healthcare costs from the pre-treatment period to the post-treatment period by cohort.

Our results suggest that there is a relationship between persistent treatment for depression and future healthcare cost trend reductions for certain treatment paths and patient cohorts. We conclude with a discussion of the results and of suggestions for future research on this topic.

Read the full report here.

Off-label drugs

Jill Van Den Bos and Daniel Perlman look at off-label drug use in the latest issue of Pharmaceutical Commerce. Here is an excerpt:

Clinical trials are clearly of great importance, but the extent of off-label use of the high-utilization drugs described above is a good illustration of one of the shortcomings of clinical trials; because they are conducted in a highly controlled environment, they may miss important facts about how drugs are used in the real world. As shown, the medical profiles of patients taking the drugs may differ significantly from what was anticipated in clinical trials. It is important for manufacturers to study real-world adherence patterns, concomitant medications, and comorbidities of actual patients once a drug is on the market.

Read the full article here.